Elevated expression of nuclear Hsp90 in invasive breast tumors

Cancer Biology and Therapy

Volumn 8, Issue 20, 2009, Pages 1952-1961

  Diehl, Malissa C ^a   Idowu, Michael O ^a   Kimmelshue, Katherine ^a   York, Timothy P ^a,b   Elmore, Lynne W ^a   Holt, Shawn E ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Breast cancer; Breast tissue arrays; Chaperones; Hsp90; Immunostaining; p23

Indexed keywords

ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 90; PROTEIN P23;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER STAGING; CELL IMMORTALIZATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRADUCTAL CARCINOMA; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; ESTROGEN RECEPTOR ALPHA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 73549122974     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.20.9639     Document Type: Article

References (43)

1. Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004; 15:651-62.
2. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa Molecular Chaperone Family: Structure, Function, and Clinical Applications. A Comprehensive Review. Pharmacol Ther 1998; 79:129-68.
3. Whitesell L, Lindquist S. Hsp90 and the chaperoning of cancer. Nature Reviews Cancer 2005; 5:761-72.
4. Sarto C, Binz PA, Mocarelli P. Heat shock proteins in human cancer. Electrophoresis 2000; 21:1218-26.
5. Dai C, Whitesell L. HSP90: A Rising Star on the Horizon of Anticancer Targets. Future Oncol 2005; 1:529-40.
6. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999; 180:10-8.
7. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 Expression is Associated with Decreased Survival in Breast Cancer. Cancer Res 2007; 67:2932-7.
8. Yano M, Naito Z, Tanaka S, Asano G. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 1996; 87:908-15.
9. Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 1999; 137:45-51.
10. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003; 14:1169-76.
11. Sharp S, Workman P. Inhibitors of the HSP90 Molecular Chaperone: Current Status. Adv in Cancer Research 2006; 95:248-323.
12. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410:439-53.
13. Pacey S, Banerji U, Judson I, Workman P. Hsp90 inhibitors in the clinic. HEP 2006; 172:331-58.
14. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19:833-42.
15. Knoblauch R, Garabedian MJ. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol Cell Biol 1999; 19:3748-59.
16. Oxelmark E, Roth JM, Brooks PC, Braunstein SE, Schneider RJ, Garabedian MJ. The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion. Mol Cell Biol 2006; 26:5205-13.
17. 2+-binding modulator protein involved in cell proliferation and in cell death. Biochim Biophys Acta 2002; 1600:68-73.
18. Mollerup J, Krogh TN, Nielson PF, Berchtold MW. Properties of the co-chaperone protein p23 erroneously attributed to ALG-2 (apoptosis-linked gene 2). FEBS Lett 2003; 555:478-82.
19. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W, Vogt T. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Derm 2004; 13:27-32.
20. Kato S, Morita T, Takenaka T, Kato M, Hirano A, Herz F, Ohama E. Stress-response (heat-shock) protein 90 expression in tumors of the central nervous system: an immunohistochemical study. Acta Neuropathol 1995; 89:184-8.
21. Kurahashi T, Miyake H, Hara I, Fujisawa M. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol 2007; 177(2):757-61.
22. Ogata M, Naito Z, Tanaka S, Moriyama Y, Asano G. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 2000; 67:177-85.
23. Romanucci M, Marinelli A, Sarli G, Della Salda L. Heat shock protein expression in canine malignant mammary tumors. BMC Cancer 2006; 6:171-82.
24. Akalin A, Elmore LW, Forsythe HL, Amaker BA, McCollum ED, Nelson PS, et al. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res 2001; 61:4791-6.
25. Elmore LW, Forsythe R, Forsythe H, Bright T, Nasim S, Endo K, Holt SE. Overexpression of telomerase-associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas. Oncology Rep 2008; 20:613-7.
26. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, Holt SE. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002; 277:35509-15.
27. Faraway JJ. Extending the linear model with R. Chapman and Hall/CRC, New York, New York 2006.
28. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407-10.
29. Zagouri F, Nonni A, Sergentanis TN, Papadimitriou CA, Michalapoulos NV, Lazaris AC, et al. Heat shock protein 90 in lobular neoplasia of the breast. BMC Cancer 2008; 8:312-8.
30. Escobar PF, Patrick RJ, Rybicki LA, Weng DE, Crowe JP. The 2003 Revised TNM Staging Systme for Breast Cancer: Results of Stage Re-classification on Survival and Future Comparisons among Stage Groups. Ann Surg Oncol 2006; 14:143-7.
31. Bai A, Gust R. Breast Cancer, Estrogen Receptor and Ligands. Arch Pharm Chem Life Sci 2009; 342:133-49.
32. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008; 23:307-14.
33. Felts SJ, Karnitz LM, Toft DO. Functioning of the Hsp90 machine in chaperoning checkpoint kinase 1 (Chk1) and the progesterone receptor (PR). Cell Stress Chaperones 2007; 12:353-63.
34. Oxelmark E, Knoblauch R, Arnal S, Su LF, Schapira M, Garabedian MJ. Genetic dissection of p23, an Hsp90 cochaperone, reveals a distinct surface involved in estrogen receptor signaling. J Biol Chem 2003; 278:36547-55.
35. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23:7721-35.
36. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14:2584-9.
37. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003; 9:1980-9.
38. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9:447-54.
39. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004; 64:8184-92.
40. Gross GE, Clark GM, Chamness GC, McGuire WL. Multiple progesterone receptor assays in human breast cancer. Cancer Res 1984; 44:836-40.
41. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 1999; 79:1564-71.
42. Kang KI, Devin J, Cadepond F, Jibard N, Guiochon-Mantel A, Baulieu E, Catelli M. In vivo functional protein-protein interaction: nuclear targeted hsp90 shifts cytoplasmic steroid receptor mutants into the nucleus. Proc Natl Acad Sci USA 1994; 91:340-4.
43. Wesche J, Małecki J, Wiedłocha A, Skjerpen CS, Claus P, Olsnes S. FGF-1 and FGF-2 require the cytosolic chaperone Hsp90 for translocation into the cytosol and the cell nucleus. J Biol Chem 2006; 281:11405-12.